3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
5
Other hematologic neoplasm
3
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
1349
Leukemia, Myeloid, Acute
1133
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
713
Leukemia
675
Precursor Cell Lymphoblastic Leukemia-Lymphoma
646
Myeloproliferative Disorders
527
Leukemia, Myelomonocytic, Chronic
424
Lymphoma, Non-Hodgkin
407
Primary Myelofibrosis
384
Multiple Myeloma
369
Leukemia, Lymphocytic, Chronic, B-Cell
367
Hodgkin Disease
348
Leukemia, Myeloid, Chronic-Phase
304
Lymphoma
291
Blast Crisis
256
Leukemia, Myeloid, Accelerated Phase
238
Lymphoma, Mantle-Cell
231
Lymphoma, Follicular
226
Burkitt Lymphoma
224
Polycythemia Vera
222
Lymphoma, Large B-Cell, Diffuse
219
Lymphoma, B-Cell, Marginal Zone
203
Congenital Abnormalities
192
Anemia, Refractory, with Excess of Blasts
187
Lymphoma, Large-Cell, Immunoblastic
182
Myelodysplastic-Myeloproliferative Diseases
175
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
173
Thrombocythemia, Essential
167
Neoplasms, Plasma Cell
161
Hematologic Neoplasms
161
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Congenital Bone Marrow Failure Syndromes
×
Myeloid
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled